Thursday, June 26, 1997
9:00 AM Eastern Time
NIAID Funds Scientists to Study Acute Infection and Early HIV Disease
- Lawrence Corey, M.D., of the Fred Hutchinson Cancer Center in
Seattle, will define the role of cytotoxic T lymphocytes (CTLs) in
controlling early infection and determine whether initial HIV-1
specific CD8+ T cell responses are predictive of subsequent
- David Ho, M.D., of the Aaron Diamond AIDS Research Center in
New York, will examine the effect of antiretroviral therapy on virus
in the blood and lymphoid tissue and on CTL response. His team
also proposes to monitor B and T cell responses.
- Jay Levy, M.D., of the University of California at San Francisco,
will evaluate the effect of therapy on viral load, the rate at which
the virus is produced, immune activation and CD8+ T cell
- Joe Margolick, M.D., of the Johns Hopkins University School of
Medicine, will explore how the virus adapts to the host during
early infection and determine whether treatment during acute
infection allows the immune system to recover its function.
- Robert Schooley, M.D., of the University of Colorado Health
Sciences Center in Denver, proposes to examine the differences
among virus in the lymph tissue and blood, and to determine the
types of cells that are involved in active versus latent infection.
- George Shaw, M.D., Ph.D., of the University of Alabama at
Birmingham, will study where HIV is distributed and sequestered
in the body and its form in various reservoirs, the dynamics of virus
reproduction and the host immunogenetic profile.
NIAID, a component of the National Institutes of Health (NIH),
supports research on AIDS, tuberculosis and other infectious diseases,
as well as allergies and immunology. NIH is an agency of the U.S.
Department of Health and Human Services.
NIAID press releases, fact sheets and other materials are available
on the Internet via the NIAID home page at http://www.niaid.nih.gov